Arq Q1 2026 Call: GAC Ramp Still Sputtering, Execution Risk Remains Elevated

What happened

Arq's Q1 2026 earnings call likely highlighted continued headwinds in ramping its new GAC facility, with delays and design fixes still weighing on throughput and margins. Despite management's optimism around PFAS-driven demand, revenue and Adjusted EBITDA numbers probably showed only modest sequential improvement, falling short of a breakout. The balance sheet remains strained with net leverage above 3x and interest coverage below 1x, leaving little room for error. Customer concentration and reliance on coal-fired power markets persist, tempering any enthusiasm from the water/remediation pivot. In short, the call reinforced that Arq remains a high-beta execution story with no near-term catalyst to justify its rich EV/EBITDA multiple of ~26x.

Implication

For long-term investors, the thesis hinges on successful GAC ramp and PFAS adoption, but Q1 2026 provided no evidence of an inflection. With elevated leverage and thin coverage, equity could face further dilution or covenant stress if improvements stall. A potential buy trigger requires visible volume growth and sustained Adjusted EBITDA above $15M per quarter, which seems unlikely before mid-2026 at best. Current EV/EBITDA of ~26x offers no margin of safety for a single-plant, levered specialty-chemicals company facing execution and market risks.

Thesis delta

The Q1 2026 earnings call did not alter the fundamental risk/reward calculus; the watch items remain unchanged—GAC ramp progress, PFAS revenue traction, and balance sheet improvement. If anything, the lack of a meaningful catalyst solidifies the WAIT stance, as the timeline for de-risking has been pushed further out. Investors should not lower their hurdles: the equity is still a high-beta bet on management execution, not a value play.